Potential Survival Benefit of Anti-Apoptosis Protein: Survivin-Derived Peptide Vaccine with and without Interferon Alpha Therapy for Patients with Advanced or Recurrent Urothelial Cancer—Results from Phase I Clinical Trials

Table 1

Profiles of patients with advanced urothelial cancer enrolled in Study 2.

No.	Age	Sex	Primary site	Recurrence site	ECOG PS	Prior chemotherapy (number of cycles)
1	72	f	UUT	LN in neck, mediastinum, and abdomen	1	MVAC (5), TIN (2)
2	36	m	Bladder	Abdominal LN Bone	0	MVAC (2), TIN (1)
3	61	m	UUT	Pelvic soft tissue	0	GC (3), TIN (2)
4	75	m	Bladder	Abdominal LN	0	MVAC (2)
5	76	m	UUT	Renal pelvis, urethra	2	GC (3), TIN (1)
6	60	f	UUT	Abdominal LN	1	MVAC (3)
7	72	f	UUT	Mediastinal LN	1	MEC (1), GEM (1), TIN (2)
8	77	m	Bladder	Lung	0	None
9	75	f	UUT	Pelvic soft tissue	1	None
10	68	m	UUT	Abdominal LN Lung	0	GC (4)
11	72	m	Bladder	Pelvic LN, liver	0	TG (1)
12	58	m	Bladder	LN in neck, abdomen, and pelvis	0	GC (2), TIN (2)
13	64	m	Bladder	LN in abdomen and pelvis	1	GC (2)
14	73	f	Bladder	Lung, liver, and bone	0	GC (3), TIN (2)
15	62	m	Bladder	Lung	1	GC (1), GCar (1)
16	74	m	Bladder	Abdominal LN	2	GC (4), TIN (2)
17	53	m	UUT	Lung, subcutaneous	2	None
18	61	m	Bladder	Lung	1	GC (6), TIN (3)
19	56	m	Bladder	Abdominal LN, liver	1	GCar (2)
20	63	f	Bladder	Abdominal LN, lung, and liver	1	GC (4)
21	73	m	Bladder	Abdominal LN, liver	0	GC (4)

UUT: upper urinary tract; LN: lymph node; ECOG PS: Eastern Cooperative Oncology Group performance status; MVAC: methotrexate, vinblastine, adriamycin, and cisplatin; TIN: paclitaxel, ifosphamide, and nedaplatin; GC: gemcitabine and cisplatin; MEC: methotrexate, etoposide, and cisplatin; GEM: gemcitabine; TG: paclitaxel and gemcitabine; GCar: gemcitabine and carboplatin.